Get the Stockscreener App
5.78
8.85%
0.47
After Hours:
5.75
-0.03
-0.52%
Verve Therapeutics Inc stock is traded at $5.78, with a volume of 867.60K.
It is up +8.85% in the last 24 hours and down -3.18% over the past month.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$5.31
Open:
$5.3
24h Volume:
867.60K
Relative Volume:
0.63
Market Cap:
$449.56M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-1.8233
EPS:
-3.17
Net Cash Flow:
$-134.39M
1W Performance:
+27.03%
1M Performance:
-3.18%
6M Performance:
+9.47%
1Y Performance:
-50.00%
1-Day Range:
$5.30
$5.87
1-Week Range:
$4.44
$5.87
52-Week Range:
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
5.78 | 449.56M | 20.65M | -192.65M | -134.39M | -3.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, In - GuruFocus.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
GSA Capital Partners LLP Reduces Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) U - GuruFocus.com
Class Action Filed Against Verve Therapeutics, Inc. (VERV)Oct - GuruFocus.com
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) s - GuruFocus.com
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Remind - GuruFocus.com
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
FY2024 EPS Forecast for Verve Therapeutics Raised by Analyst - MarketBeat
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com UK
(VERV) On The My Stocks Page - Stock Traders Daily
What is William Blair's Forecast for VERV FY2024 Earnings? - MarketBeat
FY2024 Earnings Forecast for VERV Issued By Lifesci Capital - MarketBeat
HC Wainwright Cuts Earnings Estimates for Verve Therapeutics - MarketBeat
Analyst Scoreboard: 4 Ratings For Verve Therapeutics - Benzinga
Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $14.00 at HC Wainwright - MarketBeat
Verve Therapeutics price target raised to $32 from $29 at Canaccord - TipRanks
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
VERVE Therapeutics stock target cut, keeps buy on trial updates By Investing.com - Investing.com UK
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright - TipRanks
Verve Therapeutics Reports Q3 Progress and Financials - TipRanks
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates - MSN
Verve Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1%Here's What Happened - MarketBeat
Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks
Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
VERV Deadline: VERV Investors Have Opportunity to Lead Verve The - GuruFocus.com
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - cnhinews.com
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire
VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat
Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com
Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
| Dorval Allison | Chief Financial Officer |
Nov 29 '23 |
Sale |
11.45 |
554 |
6,343 |
4,060 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):